Martingale Asset Management L P Liquidia Corp Transaction History

Martingale Asset Management L P

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$11.35 - $16.73 $211,915 - $312,365	-18,671 Reduced 57.69%	13,696 $202,000
Q2 2023 Aug 11, 2023	BUY	$6.63 - $9.9 $214,593 - $320,433	32,367 New	32,367 $254,000
Q4 2020 Feb 10, 2021	SELL	$2.6 - $5.79 $65,293 - $145,404	-25,113 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$4.34 - $8.28 $7,000 - $13,355	1,613 Added 6.86%	25,113 $123,000
Q2 2020 Aug 10, 2020	BUY	$4.86 - $11.44 $114,210 - $268,840	23,500 New	23,500 $197,000

162

36M

1.79M

380K

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $709M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

Stay updated on Martingale Asset Management L P with notifications on news.